Veracyte price to free cash flow VCYT

Market value divided by free cash flow over the last twelve months, since 2023.

Today, Oct 23, 2026: 23.2×
3-year median: 44.5×
Against its 3-year history: 13th; percentile: 0 is its lowest day, 100 its highest
3-year range: 18.8× to 292×
Peer median: 26.4×

Veracyte's price to free cash flow is 23.2× as of Oct 23, 2026.

That is below its 3-year median of 44.5×, lower than on 87% of days in the last 3 years.

Over that time it ranged from 18.8× in Mar 2026 to 292× in Jul 2023.

The median for 10 diagnostics and research stocks of a similar size is 26.4×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	23.2×	18.8×	34.1×
2025	34.2×	23.5×	62.4×
2024	55.1×	42.3×	68.9×
2023	69.1×	55.8×	292×

Against its peers

Companies in Medical - Diagnostics & Research nearest Veracyte's size, closest first, today.

Company	Price to free cash flow
VCYTVeracyte	23.2×
CDNACareDx	n/m
BLLNBillionToOne	153×
LNTHLantheus	16.8×
CAICaris Life Sciences	73.0×
BIOBio-Rad Laboratories	28.0×
RVTYRevvity	31.7×
MEDPMedpace	26.4×
LHLabcorp	23.1×
DGXQuest Diagnostics	19.8×
NRCNRC Health	22.4×
Peer median	26.4×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Veracyte

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.